Hedgehog Agonist Therapy Corrects Structural and Cognitive Deficits in a Down Syndrome Mouse Model-Reference-Cited by-同舟云学术

Hedgehog Agonist Therapy Corrects Structural and Cognitive Deficits in a Down Syndrome Mouse Model

Published:2013-09-04 Issue:201 Volume:5 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Das Ishita¹,Park Joo-Min²³,Shin Jung H.⁴,Jeon Soo Kyeong²,Lorenzi Hernan¹,Linden David J.²,Worley Paul F.²,Reeves Roger H.¹

Affiliation:

1. Department of Physiology and Institute for Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

2. Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

3. Department of Physiology, Jeju National University School of Medicine, Jeju 690-756, South Korea.

4. Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD 20857, USA.

Abstract

In a mouse model of Down syndrome, treatment with a Sonic hedgehog agonist on the day of birth normalized cerebellar structure and improved learning and memory.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference49 articles.

1. Chromosome 21 and Down syndrome: from genomics to pathophysiology

2. The use of mouse models to understand and improve cognitive deficits in Down syndrome

3. Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice

4. Reducing GABAA 5 Receptor-Mediated Inhibition Rescues Functional and Neuromorphological Deficits in a Mouse Model of Down Syndrome

5. A year of unprecedented progress in Down syndrome basic research

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vagus nerve stimulation (VNS) preventing postoperative cognitive dysfunction (POCD): two potential mechanisms in cognitive function;Molecular and Cellular Biochemistry;2024-08-13

2. Trisomy silencing by XIST: translational prospects and challenges;Human Genetics;2024-03-09

3. Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model;Neurobiology of Disease;2024-01

4. Astrocytes in human central nervous system diseases: a frontier for new therapies;Signal Transduction and Targeted Therapy;2023-10-13

5. Understanding the genetic mechanisms and cognitive impairments in Down syndrome: towards a holistic approach;Journal of Neurology;2023-08-10